Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22: 707

Erasme University Hospital, Brussels, Belgium.
Intensive Care Medicine (Impact Factor: 7.21). 08/1996; 22(7):707-10. DOI: 10.1007/BF01709751
Source: PubMed
Download full-text


Available from: Rui Moreno, May 09, 2014
  • Source
    • "To evaluate the severity of acute pancreatitis, C-reactive protein (CRP) [2], number of patients with Blood Urea Nitrogen (BUN) !20 mg/dl [30], Acute Physiology and Chronic Health Evaluation II (APACHE II) score [31] [32], Systemic Inflammatory Response Syndrome (SIRS) score [33], Sequential Organ Failure Assessment (SOFA) score [34], and Japanese severity score [35] "
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the efficacy of recombinant human soluble thrombomodulin (rTM) in preventing the development of walled-off necrosis (WON) in severe acute pancreatitis (SAP) patients. We retrospectively analyzed 54 SAP patients divided into two groups: SAP patients treated by rTM (rTM group, 24 patients) and not treated by rTM (control group, 30 patients). rTM was administered to patients with disseminated intravascular coagulation (DIC). Initially, on the admission day, we recorded patient severity and pancreatic necrosis/ischemia positive or negative. Then we investigated development of WON using 4 weeks later CT/MRI. Finally we compared the proportions of patients developing WON in the rTM group and the control group. On the admission day, the condition of patients treated by rTM was significantly worse than patients in the control group; rTM group vs. 71.8 ± 13.9 vs. 59.8 ± 15.3 years for age, 10.7 ± 3.5 vs. 8.0 ± 4.4 for Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and 3.3 ± 1.8 vs. 2.2 ± 1.8 for sequential organ failure assessment (SOFA) score (p < 0.05). We found no significant differences on the admission day in rate of pancreatic necrosis/ischemia between patients treated by rTM and controls (58.3% vs. 63.3%, p = 0.71). Nevertheless, the proportion of patients developing WON was significantly lower among those administered rTM than in those not administered rTM {29.2% (7/24 patients) vs. 56.7% (17/30 patients), p < 0.05}. Treatment of SAP patients treated by rTM may prevent progression from pancreatic necrosis/ischemia to WON. Copyright © 2015 IAP and EPC. Published by Elsevier B.V. All rights reserved.
    Pancreatology 08/2015; 15(5). DOI:10.1016/j.pan.2015.08.002 · 2.84 Impact Factor
  • Source
    • "The expected mortality rate (EMR) is calculated from the SAPS3. The Sequential Organ Failure Assessment (SOFA) score was developed to better describe the progression of organ failure with a simple scoring system [14] and is calculated daily. The SOFA is used to estimate the degree of organ dysfunction. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purposes of the study are to compare point-of-care (POC) hemostatic devices in critically ill patients with routine laboratory tests and intensive care unit (ICU) outcome scoring assessments and to describe the time course of these variables in relation to mortality rate. Patients admitted to the ICU with a prognosis of more than 3 days of stay were included. The POC devices, Multiplate platelet aggregometry, rotational thromboelastometry, and ReoRox viscoelastic tests, were used. All variables were compared between survivors and nonsurvivors. Point-of-care results were compared to prothrombin time, activated partial thromboplastin time, platelet count, fibrinogen concentration, and Sequential Organ Failure Assessment score and Simplified Acute Physiology Score 3. Blood was sampled on days 0 to 1, 2 to 3, and 4 to 10 from 114 patients with mixed diagnoses during 237 sampling events. Nonsurvivors showed POC and laboratory signs of hypocoagulation and decreased fibrinolysis over time compared to survivors. ReoRox detected differences between survivors and nonsurvivors better than ROTEM and Multiplate. All POC and routine laboratory tests showed a hypocoagulative response in nonsurvivors compared to survivors. ReoRox was better than ROTEM and Multiplate at detecting differences between surviving and nonsurviving ICU patients. However, Simplified Acute Physiology Score 3 showed the best association to mortality outcome. Copyright © 2015. Published by Elsevier Inc.
    Journal of critical care 06/2015; DOI:10.1016/j.jcrc.2015.06.014 · 2.00 Impact Factor
  • Source
    • "c Mean ± standard deviation. d SOFA score, the Sequential Organ Failure Assessment score, a scoring system to determine the extent of a person's organ function or rate of failure [12]. e P/F ratio, ratio of PaO 2 /FiO 2 , an index of arterial oxygenation efficiency that corresponds to ratio of partial pressure of arterial O 2 to the fraction of inspired O 2 . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Sepsis is a major cause of death worldwide. It triggers systemic inflammation, the role of which remains unclear. In the current study, we investigated the induction of microRNA (miRNA) during sepsis and their role in the regulation of inflammation. Patients, on days 1 and 5 following sepsis diagnosis, had reduced T cells but elevated monocytes. Plasma levels of IL-6, IL-8, IL-10 and MCP-1 dramatically increased in sepsis patients on day 1. T cells from sepsis patients differentiated primarily into Th2 cells, whereas regulatory T cells decreased. Analysis of 1163 miRNAs from PBMCs revealed that miR-182, miR-143, miR-145, miR-146a, miR-150, and miR-155 were dysregulated in sepsis patients. miR-146a downregulation correlated with increased IL-6 expression and monocyte proliferation. Bioinformatics analysis uncovered the immunological associations of dysregulated miRNAs with clinical disease. The current study demonstrates that miRNA dysregulation correlates with clinical manifestations and inflammation, and therefore remains a potential therapeutic target against sepsis.
    Cytokine 01/2015; 71(1):89–100. DOI:10.1016/j.cyto.2014.09.003 · 2.66 Impact Factor
Show more